FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease →
Drugs & FDA — FDA · fda.gov · Jul 1
The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with…
Large Registry Study Questions Utility of Plasma CGRP as Diagnostic Biomarker for Migraine →
Drugs & FDA — NeurologyLive · neurologylive.com · Jul 12
In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a…
Looking Beyond Gene Therapy for Treating Charcot-Marie-Tooth Disease: Carla Taveggia, PhD →
Drugs & FDA — NeurologyLive · neurologylive.com · Jul 11
The director of the Division of Neuroscience at IRCCS Istituto Ortopedico Rizzoli discussed why targeting shared biologic pathways, rather than individual mutations, may represent a promising…
Active Smoking Associated With Doubled Relapse Rate in MOGAD →
Drugs & FDA — NeurologyLive · neurologylive.com · Jul 11
An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, while past smokers showed no elevated risk, supporting smoking cessation as…
AAIC 2026 Preview: David Wolk, MD, on Biomarkers, Disease Heterogeneity, and What's Next in Alzheimer Research →
Drugs & FDA — NeurologyLive · neurologylive.com · Jul 10
Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to…
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen →
Drugs & FDA — FierceBiotech · fiercebiotech.com
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures →
Drugs & FDA — FierceBiotech · fiercebiotech.com
GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both “next generation” drugs involved flunk clinical trials.
Satellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readout →
Drugs & FDA — FierceBiotech · fiercebiotech.com
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule “could re-imagine the ... therapeutic…
Hospital ACOs raised Medicare spending 0.8% under ACO REACH: 8 notes →
Healthcare System — Becker's Hospital Review · beckershospitalreview.com · Jul 10
Health system-led standard ACOs increased Medicare spending by 0.8% over ACO REACH’s first three years, while ACOs built around independent physician practices cut spending by the same 0.8%, a…
A Look at 1115 Waiver Evaluations for Medicaid Payments to Institutions of Mental Disease (IMD) for Substance Use Disorder →
Healthcare System — KFF · kff.org · Jul 9
As SUD IMD waiver evaluations and renewals are becoming available, states face a shifting Medicaid and policy and waiver landscape. This brief examines findings from the first available summative…
Digital Health Tools and Technologies: An Overview of CMS’ Recent Efforts to Expand Their Use in Medicare →
Healthcare System — KFF · kff.org · Jul 7
As an increasing share of older adults have adopted digital health technologies over the past several years, and with most expressing interest in using them to manage their health care, the…
What Did Your First Car Teach You About Money and Finances? →
Financial — White Coat Investor · whitecoatinvestor.com · Jul 12
We talked to a number of WCIers about their first car and what it taught them about money and finances. Here's what they told us.
The post What Did Your First Car Teach You About Money and…
Why I’m Changing My Asset Allocation Before I Become an Attending →
Financial — White Coat Investor · whitecoatinvestor.com · Jul 11
As I look ahead to graduating from residency, here are my thoughts about whether and when I should change my portfolio's asset allocation.
The post Why I’m Changing My Asset Allocation Before I…
The Quiet Corruption of Medical Research →
Interesting Reads — Doximity Op-Med · opmed.doximity.com · Jul 9